Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-09-04
2007-09-04
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S143100, C424S178100, C435S070210, C530S388100, C530S388220, C530S391300
Reexamination Certificate
active
10240912
ABSTRACT:
The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labelled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha- or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labelled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.
REFERENCES:
patent: 4873316 (1989-10-01), Meade et al.
patent: 4939087 (1990-07-01), Van Wie et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5541294 (1996-07-01), Horowitz et al.
patent: 5648472 (1997-07-01), Gehringer et al.
patent: 6241961 (2001-06-01), Benes et al.
patent: 195 21 388 (1996-12-01), None
patent: 197 44 531.4 (1997-10-01), None
patent: 0 727 480 (1996-08-01), None
patent: 0 585 570 (1998-11-01), None
patent: WO86/05202 (1986-09-01), None
patent: WO96/22310 (1996-07-01), None
Kuby et al., 1994, Immunology, second edition, pp. 85-96.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Jantscheff et al, J Leukocyte Biology 59: 891-901, Jun. 1996.
Bunjes et al, Blood 98(3): 565-572, Aug. 2001.
Harlow et al, n Antibodies a Laboratory Manual, 1998, Cold Spring harbor laboratory publication, Cold Spring Harobr, NY, pp. 285-311.
Troccoli et al, Biologicals 26: 321-329, 1998.
Stahl et al.: “Evidence for specific recognition sites mediating clearance of lysosomal enzymes in vivo”, in: PNAS, vol. 73, No. 11, pp. 4045-4049.
Lindmo et al.: “Determination of the Immu oreactive fraction of radiolabeled monocional antibodies . . . ”, in: Journal of Immun. Methods, pp. 77-89, 1984.
Seitz et al.: “Preparation and evaluation of the rhenium-188-labeled anti-NCA antigen monoclonal antibody . . . ”, In: Europ. Jour. of Nuc. Med., Oct. 10, 1999.
Jagoda et al.: “An affinity column method for determination of the immunoreactivity of . . . ”, In: Journ. of Immun. Meth., Nov. 12, 1993.
Mattes: “Limitations of the Lindmo method in determining antibody immunoreactivity”, in: In. Int. J. Cancer, pp. 286-288, 1995.
Morales-Morales et al.: “Biodistribution of 99m-Tc-labaled anti-human epidermal growth factor . . . ”, in: Nucl. Med. & Biol., vol. 26, pp. 275-279, 1999.
Boven et al.: “Selective cytotoxicity of 125-l-labeled monoclonal antibody T101 in human malignant . . . ”, in: Blood, vol. 67, No. 2, 1986, pp. 429-435.
Schubinger et al.: “Assessment of the binding properties of granuloszint”, in: Eur. Journ. of Nucl. Med., vol. 15, 1989, pp. 605-608.
Bosslet et al.: “Quantitative cosiderations suporting the irrelevance of circulating serum CEA . . . ”, in: Eur. J. of Nucl. Med., vol. 14, 1988.
Bosslet et al.: “Immunohistochemical localization and molecular characteristics of three . . . ”, in: J. Cancer, vol. 36, 1985, pp. 75-84.
Bosslet et al.: “Molecular and functional characterisation of a fusion protein suited . . . ”, in: Br. J. Cancer, vol. 65, 1992, pp. 234-238.
Alles et al.: “Immunohistochemical and Immunochemical characterization . . . ”, in: Jour. of Histochemistry and Cytochemistry, vol. 34, No. 2, 1986.
Hale et al.: “Therapeutic potential of rat monoclonal antibodies:isotype specificity of . . . ”, in: Jou. of Immunology, vol. 134, No. 5, May 1985.
Cobbold et al.: “Non-lineage, LFA-1 family and leucocyte common antigens: new and . . . ”, in: Oxford, pp. 788-803, approx. 1988.
Berthold et al.: “Detection of minial disease in bone marrow of neuroblastoma patients . . . ”, in: Pediatric Hemat. & Oncol., vol. 6, 1989, pp. 73-83.
Schwarz et al.: “A novel approach to Tc-99m-labeled monoclonal antibodies”, in: Jour. f. Nucl. Med., vol. 28, No. 4, Apr. 1987, p. 721.
A. Bruynck et al: Characterisation of a humanised bispecific monoclonal antibody for cancer therapy, in: BR. J. Cancer, pp. 436-440, 1993.
Dux et al.: “Determination of immunoreactive fraction and kinetic parameters of a radiolabeled monocional antibody in the absence of antigen excess”, in: Journal of Immunological Methods, pp. 175-183, 1991.
Seccamani et al.: “Standardization of an immunoreactivity test for radiolabelled monoclonal antibodies”, in: Nuklearmedizin Supplement, pp. 709-711, 1989.
Guo Xuegang et al.: “A method to determine the affinity constant of an antibody and antigen density on cell surfaces”, in: Science Press, 1993.
R. Waibel et al.: “Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(l)-carbonyl complex”, Nature Biotechnology, Sep. 1999, vol. 17, XP-002156715, pp. 897-901.
Benes Ivan
Thomsen-Bosslet Silke
Chan Christina
Day Ursula B.
Feiereisen Henry M.
Huynh Phuong
Scintec Diagnostics GmbH
LandOfFree
Proteins with a high immunoreactivity and a method for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteins with a high immunoreactivity and a method for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteins with a high immunoreactivity and a method for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3723984